The phase 1 trial results, published Feb. 19 in Nature, evaluated the personalized mRNA neoantigen vaccine autogene cevumeran in combination with surgery, immunotherapy drug atezolizumab and ...
A gene called high mobility group A1 (HMGA1) may be the key that opens the door to the development of colon cancer, according ...
Zealand Pharma reports 2024 results but no partnering deal for petrelintide. CEO Adam Steensberg remains confident despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback